Grant provides an unprecedented opportunity to further build out meaningful programs and services for people with lupus and physicians.
Funds raised from the Lupus Foundation of America’s Evening of Hope Gala will be dedicated to lupus research
The Lupus Foundation of America research grants will support important studies on immune cells, pediatric lupus, stem cells, biomarkers, and environmental triggers of lupus.
A new Congressional report includes an article contributed by the Lupus Foundation of America on health disparities among people with lupus and current efforts to improve treatment and diagnosis in minority communities.
The Lupus Foundation of America (Foundation) announced today that Conrad Gehrmann of Seattle, Washington was elected as Chair of the Foundation’s National Board of Directors at a recent annual meeting. Gehrmann will provide organizational leadership and oversee the Foundation’s strategic initiatives to bring national attention and increased public and private resources to lupus, a potentially life-threatening and unpredictable chronic autoimmune disease that affects an estimated 1.5 million Americans.
Results from a study of epratuzumab were released today. It did not meet its primary endpoint of clinically reducing the severity of lupus in people with mild to moderate disease. The following is a statement from Sandra C. Raymond, President and CEO
Lupus Foundation of America’s Collaboration in PARTNERS Seeks to Improve Pediatric Research and Care
Learn more about PARTNERS (Patients, Advocates and Rheumatology Teams Network for Research and Service), a new initiative.
Today, the U.S. House of Representatives passed the 21st Century Cures Act, legislation that has the potential to improve the drug development process and bring new and vital treatments forward for people with chronic diseases like lupus.